BioMarin Pharmaceutical Inc. vs CRISPR Therapeutics AG: SG&A Expense Trends

Biotech Giants: A Decade of SG&A Expense Evolution

__timestampBioMarin Pharmaceutical Inc.CRISPR Therapeutics AG
Wednesday, January 1, 20143021560005114000
Thursday, January 1, 201540227100013403000
Friday, January 1, 201647659300031056000
Sunday, January 1, 201755433600035845000
Monday, January 1, 201860435300048294000
Tuesday, January 1, 201968092400063488000
Wednesday, January 1, 202073766900088208000
Friday, January 1, 2021759375000102802000
Saturday, January 1, 2022854009000102464000
Sunday, January 1, 202393730000076162000
Monday, January 1, 2024100902500072977000
Loading chart...

Unlocking the unknown

SG&A Expense Trends: BioMarin vs. CRISPR

In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, BioMarin Pharmaceutical Inc. and CRISPR Therapeutics AG have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. BioMarin's SG&A expenses have surged by over 200% from 2014 to 2023, reflecting its aggressive expansion and operational scaling. In contrast, CRISPR Therapeutics AG, a relatively newer player, has seen its SG&A expenses grow by approximately 1,400% during the same period, indicative of its rapid growth and investment in groundbreaking gene-editing technologies. By 2023, BioMarin's expenses were nearly 12 times higher than CRISPR's, highlighting the different stages of maturity and market strategies of these companies. This financial insight not only underscores the competitive landscape but also offers a glimpse into the strategic priorities shaping the future of biotechnology.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025